| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors ("Viking").
Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx.
"We're pleased to engage with ArrowMark and Viking and their latest NewCo as our newest technology and discovery services partner. ArrowMark and Viking have an established heritage of incredibly successful biotech investments, high-science analysis and value creation," said Matt Foehr, President and Chief Executive Officer of OmniAb. "This latest transaction highlights how we can leverage our novel transgenic chicken-based technologies to deliver value through multiple innovative strategies across different time horizons."
"We believe that some of the most important and valuable next-generation drug targets can be addressed by leveraging OmniAb's novel suite of technologies and services," said Tony Yao, M.D., Ph.D., Life Science Portfolio Manager for ArrowMark.
Posted In: OABI
